CMAJ 2021;193: E1836e41
Truveta Research study : At 52 weeks, weight loss was 18.2% for Mounjaro (tirzepatide ADM) compared to 10.6% for Ozempic (semaglutide ADM) for patients without type 2 diabetes (T2D) The lower percentages in the Truveta Research study likely reflect a shorter timeframe (52 weeks instead of 72) and the use of ADM versions, which can have lower doses
valor de p de interaccin=0,689)
Theres no specific stopping protocol or rebound effect to worry about with topical use
Most butyrate-produced microbiota in the order Clostridiales are widely distributed in several clusters, including clusters IV, XIVa, XVI, and I (53)
This is particularly valuable for addressing genes with defective proteins that are difficult to be targeted with conventional drugs, showing considerable potential in treating rare, chronic, infectious diseases and other metabolic disorders